Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Breast Cancer Research
Erschienen in: Breast Cancer Research 1/2012

01.02.2012 | Review

The role and function of cadherins in the mammary gland

verfasst von: Jennifer L Andrews, Alvin C Kim, Julie R Hens

Erschienen in: Breast Cancer Research | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Cadherins are transmembrane receptors that function through calcium-dependent homophilic and heterophilic interactions that provide cell-cell contact and communication in many different organ systems. In the mammary gland only a few of the cadherins that make up this large superfamily of proteins have been characterized. Frequently in metastatic breast cancer, the genes for cadherins are epigenetically silenced, mutated, or regulated differently. During epithelial-mesenchymal transition, cadherins that are expressed normally in the epithelial cells are down-regulated, while cadherins expressed in the mesenchyme are up-regulated. This process is known as cadherin switching, and its regulation can sometimes facilitate the increased motility, invasiveness and proliferation that occurs in metastatic cancer cells. Depending on the context, however, cell motility, invasiveness, proliferation and expression of mesenchymal markers can be independently modulated from cadherin expression, leading to partial epithelial-mesenchymal transitions and even mesenchymal-epithelial transitions (METs). This review will summarize the current understanding of cadherins found in the mammary gland and what is known about their mechanism of regulation in the mammary gland during normal physiological conditions and in breast cancer.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Peinado H, Portillo F, Cano A: Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol. 2004, 48: 365-375. 10.1387/ijdb.041794hp.CrossRefPubMed
2.
3.
Hazan RB, Kang L, Whooley BP, Borgen PI: N-cadherin promotes adhesion between invasive breast cancer cells and the stroma. Cell Adhes Commun. 1997, 4: 399-411. 10.3109/15419069709004457.CrossRefPubMed
4.
Radice GL, Sauer CL, Kostetskii I, Peralta Soler A, Knudsen KA: Inappropriate P-cadherin expression in the mouse mammary epithelium is compatible with normal mammary gland function. Differentiation. 2003, 71: 361-373. 10.1046/j.1432-0436.2003.7106005.x.CrossRefPubMed
5.
Paredes J, Milanezi F, Reis-Filho JS, Leitao D, Athanazio D, Schmitt F: Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer?. Pathol Res Pract. 2002, 198: 795-801. 10.1078/0344-0338-00338.CrossRefPubMed
6.
Sommers CL: The role of cadherin-mediated adhesion in breast cancer. J Mammary Gland Biol Neoplasia. 1996, 1: 219-229. 10.1007/BF02013645.CrossRefPubMed
7.
Paredes J, Milanezi F, Viegas L, Amendoeira I, Schmitt F: P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast. Virchows Arch. 2002, 440: 16-21. 10.1007/s004280100487.CrossRefPubMed
8.
Agiostratidou G, Li M, Suyama K, Badano I, Keren R, Chung S, Anzovino A, Hulit J, Qian B, Bouzahzah B, Eugenin E, Loudig O, Phillips GR, Locker J, Hazan RB: Loss of retinal cadherin facilitates mammary tumor progression and metastasis. Cancer Res. 2009, 69: 5030-5038.CrossRefPubMedPubMedCentral
9.
10.
Wheelock MJ, Johnson KR: Cadherin-mediated cellular signaling. Curr Opin Cell Biol. 2003, 15: 509-514. 10.1016/S0955-0674(03)00101-7.CrossRefPubMed
11.
Bracke ME, Depypere H, Labit C, Van Marck V, Vennekens K, Vermeulen SJ, Maelfait I, Philippe J, Serreyn R, Mareel MM: Functional downregulation of the E-cadherin/catenin complex leads to loss of contact inhibition of motility and of mitochondrial activity, but not of growth in confluent epithelial cell cultures. Eur J Cell Biol. 1997, 74: 342-349.PubMed
12.
Tryndyak VP, Beland FA, Pogribny IP: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer. 2010, 126: 2575-2583.PubMed
13.
Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009, 28: 151-166. 10.1007/s10555-008-9179-y.CrossRefPubMed
14.
Fedor-Chaiken M, Hein PW, Stewart JC, Brackenbury R, Kinch MS: E-cadherin binding modulates EGF receptor activation. Cell Commun Adhes. 2003, 10: 105-118.CrossRefPubMed
15.
Suyama K, Shapiro I, Guttman M, Hazan RB: A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell. 2002, 2: 301-314. 10.1016/S1535-6108(02)00150-2.CrossRefPubMed
16.
Fukata M, Kaibuchi K: Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol. 2001, 2: 887-897. 10.1038/35103068.CrossRefPubMed
17.
Derycke LD, Bracke ME: N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol. 2004, 48: 463-476. 10.1387/ijdb.041793ld.CrossRefPubMed
18.
Cavallaro U, Schaffhauser B, Christofori G: Cadherins and the tumour progression: is it all in a switch?. Cancer Lett. 2002, 176: 123-128. 10.1016/S0304-3835(01)00759-5.CrossRefPubMed
19.
Franberg J, Svensson AI, Winblad B, Karlstrom H, Frykman S: Minor contribution of presenilin 2 for gamma-secretase activity in mouse embryonic fibroblasts and adult mouse brain. Biochem Biophys Res Commun. 2011, 404: 564-568. 10.1016/j.bbrc.2010.12.029.CrossRefPubMed
20.
Berx G, van Roy F: Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol. 2009, 1: a003129-10.1101/cshperspect.a003129.CrossRefPubMedPubMedCentral
21.
Daniel CW, Strickland P, Friedmann Y: Expression and functional role of E-and P-cadherins in mouse mammary ductal morphogenesis and growth. Dev Biol. 1995, 169: 511-519. 10.1006/dbio.1995.1165.CrossRefPubMed
22.
Turashvili G, McKinney SE, Goktepe O, Leung SC, Huntsman DG, Gelmon KA, Los G, Rejto PA, Aparicio SA: P-cadherin expression as a prognostic biomarker in a 3992 case tissue microarray series of breast cancer. Mod Pathol. 2011, 24: 64-81. 10.1038/modpathol.2010.189.CrossRefPubMed
23.
Paredes J, Albergaria A, Oliveira JT, Jeronimo C, Milanezi F, Schmitt FC: P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation. Clin Cancer Res. 2005, 11: 5869-5877. 10.1158/1078-0432.CCR-05-0059.CrossRefPubMed
24.
Paredes J, Correia AL, Ribeiro AS, Albergaria A, Milanezi F, Schmitt FC: P-cadherin expression in breast cancer: a review. Breast Cancer Res. 2007, 9: 214-10.1186/bcr1774.CrossRefPubMedPubMedCentral
25.
Zhang CC, Yan Z, Zhang Q, Kuszpit K, Zasadny K, Qiu M, Painter CL, Wong A, Kraynov E, Arango ME, Mehta PP, Popoff I, Casperson GF, Los G, Bender S, Anderes K, Christensen JG, VanArsdale T: PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res. 2010, 16: 5177-5188.CrossRefPubMed
26.
Zou W, Hu CH, Zhou JP: [Relationship between the expression of E-cadherin-catenins and alpha-, beta-, gamma-catenin and the metastasis and prognosis of breast cancer]. Hunan Yi Ke Da Xue Xue Bao. 2002, 27: 499-502.PubMed
27.
Labelle M, Schnittler HJ, Aust DE, Friedrich K, Baretton G, Vestweber D, Breier G: Vascular endothelial cadherin promotes breast cancer progression via transforming growth factor beta signaling. Cancer Res. 2008, 68: 1388-1397. 10.1158/0008-5472.CAN-07-2706.CrossRefPubMed
28.
Okazaki M, Takeshita S, Kawai S, Kikuno R, Tsujimura A, Kudo A, Amann E: Molecular cloning and characterization of OB-cadherin, a new member of cadherin family expressed in osteoblasts. J Biol Chem. 1994, 269: 12092-12098.PubMed
29.
Valencia X, Higgins JM, Kiener HP, Lee DM, Podrebarac TA, Dascher CC, Watts GF, Mizoguchi E, Simmons B, Patel DD, Bhan AK, Brenner MB: Cadherin-11 provides specific cellular adhesion between fibroblast-like synoviocytes. J Exp Med. 2004, 200: 1673-1679. 10.1084/jem.20041545.CrossRefPubMedPubMedCentral
30.
Kiener HP, Niederreiter B, Lee DM, Jimenez-Boj E, Smolen JS, Brenner MB: Cadherin 11 promotes invasive behavior of fibroblast-like synoviocytes. Arthritis Rheum. 2009, 60: 1305-1310. 10.1002/art.24453.CrossRefPubMedPubMedCentral
31.
Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, Takeichi M, Brenner MB: Cadherin-11 in synovial lining formation and pathology in arthritis. Science. 2007, 315: 1006-1010. 10.1126/science.1137306.CrossRefPubMed
32.
Pishvaian MJ, Feltes CM, Thompson P, Bussemakers MJ, Schalken JA, Byers SW: Cadherin-11 is expressed in invasive breast cancer cell lines. Cancer Res. 1999, 59: 947-952.PubMed
33.
Feltes CM, Kudo A, Blaschuk O, Byers SW: An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res. 2002, 62: 6688-6697.PubMed
34.
Tamura D, Hiraga T, Myoui A, Yoshikawa H, Yoneda T: Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol. 2008, 33: 17-24.PubMed
35.
Farina AK, Bong YS, Feltes CM, Byers SW: Post-transcriptional regulation of cadherin-11 expression by GSK-3 and beta-catenin in prostate and breast cancer cells. PLoS One. 2009, 4: e4797-10.1371/journal.pone.0004797.CrossRefPubMedPubMedCentral
36.
Boscher C, Mege RM: Cadherin-11 interacts with the FGF receptor and induces neurite outgrowth through associated downstream signalling. Cell Signal. 2008, 20: 1061-1072. 10.1016/j.cellsig.2008.01.008.CrossRefPubMed
37.
Hebbard LW, Garlatti M, Young LJ, Cardiff RD, Oshima RG, Ranscht B: T-cadherin supports angiogenesis and adiponectin association with the vasculature in a mouse mammary tumor model. Cancer Res. 2008, 68: 1407-1416. 10.1158/0008-5472.CAN-07-2953.CrossRefPubMedPubMedCentral
38.
Ranscht B, Dours-Zimmermann MT: T-cadherin, a novel cadherin cell adhesion molecule in the nervous system lacks the conserved cytoplasmic region. Neuron. 1991, 7: 391-402. 10.1016/0896-6273(91)90291-7.CrossRefPubMed
39.
Takeuchi T, Misaki A, Chen BK, Ohtsuki Y: H-cadherin expression in breast cancer. Histopathology. 1999, 35: 87-88. 10.1046/j.1365-2559.1999.0728c.x.CrossRefPubMed
40.
Adachi Y, Takeuchi T, Nagayama T, Ohtsuki Y, Furihata M: Zeb1-mediated T-cadherin repression increases the invasive potential of gallbladder cancer. FEBS Lett. 2009, 583: 430-436. 10.1016/j.febslet.2008.12.042.CrossRefPubMed
41.
Lee SW: H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med. 1996, 2: 776-782. 10.1038/nm0796-776.CrossRefPubMed
42.
Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD, Gazdar AF: Loss of expression and aberrant methylation of the CDH13 (H-cadherin) gene in breast and lung carcinomas. Cancer Res. 2001, 61: 4556-4560.PubMed
43.
Cool M, Jolicoeur P: Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice. Cancer Res. 1999, 59: 2438-2444.PubMed
44.
Hulpiau P, van Roy F: New insights into the evolution of metazoan cadherins. Mol Biol Evol. 2011, 28: 647-657.CrossRefPubMed
45.
Qi C, Zhu YT, Hu L, Zhu YJ: Identification of Fat4 as a candidate tumor suppressor gene in breast cancers. Int J Cancer. 2009, 124: 793-798. 10.1002/ijc.23775.CrossRefPubMedPubMedCentral
46.
Mao Y, Mulvaney J, Zakaria S, Yu T, Morgan KM, Allen S, Basson MA, Francis-West P, Irvine KD: Characterization of a Dchs1 mutant mouse reveals requirements for Dchs1-Fat4 signaling during mammalian development. Development. 2011, 138: 947-957. 10.1242/dev.057166.CrossRefPubMedPubMedCentral
47.
Yu JS, Koujak S, Nagase S, Li CM, Su T, Wang X, Keniry M, Memeo L, Rojtman A, Mansukhani M, Hibshoosh H, Tycko B, Parsons R: PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer. Oncogene. 2008, 27: 4657-4665. 10.1038/onc.2008.101.CrossRefPubMedPubMedCentral
48.
Yasuda S, Tanaka H, Sugiura H, Okamura K, Sakaguchi T, Tran U, Takemiya T, Mizoguchi A, Yagita Y, Sakurai T, De Robertis EM, Yamagata K: Activity-induced protocadherin arcadlin regulates dendritic spine number by triggering N-cadherin endocytosis via TAO2beta and p38 MAP kinases. Neuron. 2007, 56: 456-471. 10.1016/j.neuron.2007.08.020.CrossRefPubMedPubMedCentral
49.
Santiago-Josefat B, Esselens C, Bech-Serra JJ, Arribas J: Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors. J Biol Chem. 2007, 282: 8325-8331. 10.1074/jbc.M608826200.CrossRefPubMed
50.
Klus GT, Rokaeus N, Bittner ML, Chen Y, Korz DM, Sukumar S, Schick A, Szallasi Z: Down-regulation of the desmosomal cadherin desmocollin 3 in human breast cancer. Int J Oncol. 2001, 19: 169-174.PubMed
51.
Thiery JP: Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003, 15: 740-746. 10.1016/j.ceb.2003.10.006.CrossRefPubMed
52.
Christiansen JJ, Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res. 2006, 66: 8319-8326. 10.1158/0008-5472.CAN-06-0410.CrossRefPubMed
53.
Chao YL, Shepard CR, Wells A: Breast carcinoma cells re-express E-cadherin during mesenchymal to epithelial reverting transition. Mol Cancer. 2010, 9: 179-10.1186/1476-4598-9-179.CrossRefPubMedPubMedCentral
54.
Dubois-Marshall S, Thomas JS, Faratian D, Harrison DJ, Katz E: Two possible mechanisms of epithelial to mesenchymal transition in invasive ductal breast cancer. Clin Exp Metastasis. 2011, 28: 811-818. 10.1007/s10585-011-9412-x.CrossRefPubMed
55.
Lundgren K, Nordenskjold B, Landberg G: Hypoxia, Snail and incomplete epithelial-mesenchymal transition in breast cancer. Br J Cancer. 2009, 101: 1769-1781. 10.1038/sj.bjc.6605369.CrossRefPubMedPubMedCentral
56.
Park SM, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22: 894-907. 10.1101/gad.1640608.CrossRefPubMedPubMedCentral
57.
Berx G, Cleton-Jansen AM, Strumane K, de Leeuw WJ, Nollet F, van Roy F, Cornelisse C: E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene. 1996, 13: 1919-1925.PubMed
58.
Graff JR, Gabrielson E, Fujii H, Baylin SB, Herman JG: Methylation patterns of the E-cadherin 5' CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem. 2000, 275: 2727-2732. 10.1074/jbc.275.4.2727.CrossRefPubMed
59.
Lynch HT, Grady W, Lynch JF, Tsuchiya KD, Wiesner G, Markowitz SD: E-cadherin mutation-based genetic counseling and hereditary diffuse gastric carcinoma. Cancer Genet Cytogenet. 2000, 122: 1-6. 10.1016/S0165-4608(00)00273-9.CrossRefPubMed
60.
Nass SJ, Herman JG, Gabrielson E, Iversen PW, Parl FF, Davidson NE, Graff JR: Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer. Cancer Res. 2000, 60: 4346-4348.PubMed
61.
Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J: Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011, 30: 1436-1448.CrossRefPubMed
62.
Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA: ZEB1-responsive genes in non-small cell lung cancer. Cancer Lett. 2011, 300: 66-78. 10.1016/j.canlet.2010.09.007.CrossRefPubMed
63.
Hajra KM, Chen DY, Fearon ER: The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002, 62: 1613-1618.PubMed
64.
Hajra KM, Fearon ER: Cadherin and catenin alterations in human cancer. Genes Chromosomes Cancer. 2002, 34: 255-268. 10.1002/gcc.10083.CrossRefPubMed
65.
Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, Cano A: The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci. 2003, 116: 499-511. 10.1242/jcs.00224.CrossRefPubMed
66.
Martin TA, Watkins G, Lane J, Jiang WG: Assessing microvessels and angiogenesis in human breast cancer, using VE-cadherin. Histopathology. 2005, 46: 422-430. 10.1111/j.1365-2559.2005.02104.x.CrossRefPubMed
67.
Chen X, Ding J, Gao W, Yi X, Wang H, Li H: [Expression of E-cadherin in non-small cell lung cancer: correlation with lymphatic metastasis and prognosis.]. Zhongguo Fei Ai Za Zhi. 2002, 5: 260-262.PubMed
68.
Nishimura Y, Yoshioka K, Bernard O, Bereczky B, Itoh K: A role of LIM kinase 1/cofilin pathway in regulating endocytic trafficking of EGF receptor in human breast cancer cells. Histochem Cell Biol. 2006, 126: 627-638. 10.1007/s00418-006-0198-x.CrossRefPubMed
69.
Postigo AA, Depp JL, Taylor JJ, Kroll KL: Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J. 2003, 22: 2453-2462. 10.1093/emboj/cdg226.CrossRefPubMedPubMedCentral
70.
Postigo AA: Opposing functions of ZEB proteins in the regulation of the TGFbeta/BMP signaling pathway. EMBO J. 2003, 22: 2443-2452. 10.1093/emboj/cdg225.CrossRefPubMedPubMedCentral
71.
Liu T, Dong XG, Wang Y, Yan Y, Zhang JJ: [The mechanism of twist gene regulation during the retina angiogenesis.]. Zhonghua Yan Ke Za Zhi. 2008, 44: 634-639.PubMed
72.
Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM: Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008, 68: 2479-2488. 10.1158/0008-5472.CAN-07-2559.CrossRefPubMed
73.
Sanchez-Tillo E, Lazaro A, Torrent R, Cuatrecasas M, Vaquero EC, Castells A, Engel P, Postigo A: ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodeling protein BRG1. Oncogene. 2010, 29: 3490-3500. 10.1038/onc.2010.102.CrossRefPubMed
74.
Burke JM: Epithelial phenotype and the RPE: is the answer blowing in the Wnt?. Prog Retin Eye Res. 2008, 27: 579-595. 10.1016/j.preteyeres.2008.08.002.CrossRefPubMedPubMedCentral
75.
Wang F, Sloss C, Zhang X, Lee SW, Cusack JC: Membrane-bound heparin-binding epidermal growth factor like growth factor regulates E-cadherin expression in pancreatic carcinoma cells. Cancer Res. 2007, 67: 8486-8493. 10.1158/0008-5472.CAN-07-0498.CrossRefPubMed
76.
Jiang WG: E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surg. 1996, 83: 437-446. 10.1002/bjs.1800830404.CrossRefPubMed
77.
Hamamori Y, Wu HY, Sartorelli V, Kedes L: The basic domain of myogenic basic helix-loop-helix (bHLH) proteins is the novel target for direct inhibition by another bHLH protein, Twist. Mol Cell Biol. 1997, 17: 6563-6573.CrossRefPubMedPubMedCentral
78.
Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ: Twist is a potential oncogene that inhibits apoptosis. Genes Dev. 1999, 13: 2207-2217. 10.1101/gad.13.17.2207.CrossRefPubMedPubMedCentral
79.
Castanon I, Von Stetina S, Kass J, Baylies MK: Dimerization partners determine the activity of the Twist bHLH protein during Drosophila mesoderm development. Development. 2001, 128: 3145-3159.PubMed
80.
Oda H, Tsukita S, Takeichi M: Dynamic behavior of the cadherin-based cell-cell adhesion system during Drosophila gastrulation. Dev Biol. 1998, 203: 435-450. 10.1006/dbio.1998.9047.CrossRefPubMed
81.
Wang S, Jiang Y, Huang H, Yang Q: [Expression and correlation with metastasis of E-cadherin, CD44H, matrix metalloproteinase-3, nm23H1 and VEGF in nasopharyngeal carcinoma.]. Lin Chuang Er Bi Yan Hou Ke Za Zhi. 2004, 18: 470-472.PubMed
82.
Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S: Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet. 2001, 357: 1335-1336. 10.1016/S0140-6736(00)04501-3.CrossRefPubMed
83.
Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA: Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004, 117: 927-939. 10.1016/j.cell.2004.06.006.CrossRefPubMed
84.
Howe LR, Watanabe O, Leonard J, Brown AM: Twist is up-regulated in response to Wnt1 and inhibits mouse mammary cell differentiation. Cancer Res. 2003, 63: 1906-1913.PubMed
85.
Yang MH, Wu KJ: TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle. 2008, 7: 2090-2096. 10.4161/cc.7.14.6324.CrossRefPubMed
86.
Yang L, Jiang Y, Wu SF, Zhou MY, Wu YL, Chen GQ: CCAAT/enhancer-binding protein alpha antagonizes transcriptional activity of hypoxia-inducible factor 1 alpha with direct protein-protein interaction. Carcinogenesis. 2008, 29: 291-298.CrossRefPubMed
87.
88.
Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, Hung MC: Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat Cell Biol. 2004, 6: 931-940. 10.1038/ncb1173.CrossRefPubMed
89.
de Herreros AG, Peiro S, Nassour M, Savagner P: Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia. 2010, 15: 135-147. 10.1007/s10911-010-9179-8.CrossRefPubMedPubMedCentral
Metadaten
Titel
The role and function of cadherins in the mammary gland
verfasst von
Jennifer L Andrews
Alvin C Kim
Julie R Hens
Publikationsdatum
01.02.2012
Verlag
BioMed Central
Erschienen in
Breast Cancer Research / Ausgabe 1/2012
Elektronische ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3065

Weitere Artikel der Ausgabe 1/2012

Breast Cancer Research 1/2012 Zur Ausgabe

Research article

Balancing harms and benefits of service mammography screening programs: a cohort study

Editorial

The dynamic yin-yang interaction of CXCR4 and CXCR7 in breast cancer metastasis

Research article

Germline DNA copy number variation in familial and early-onset breast cancer

Research article

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells

Research article

Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis

Research article

STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas

Neu im Fachgebiet Onkologie

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

03.06.2024 NSCLC Nachrichten

Wie stark Menschen mit fortgeschrittenem NSCLC von einer Therapie mit Immun-Checkpoint-Hemmern profitieren, hängt offenbar auch davon ab, wie sehr die Diagnose ihre psychische Verfassung erschüttert

Antikörper mobilisiert Neutrophile gegen Krebs

03.06.2024 Onkologische Immuntherapie Nachrichten

Ein bispezifischer Antikörper formiert gezielt eine Armee neutrophiler Granulozyten gegen Krebszellen. An den Antikörper gekoppeltes TNF-alpha soll die Zellen zudem tief in solide Tumoren hineinführen.

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise